We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,200.60
Bid: 1,197.40
Ask: 1,198.00
Change: 9.80 (0.82%)
Spread: 0.60 (0.05%)
Open: 1,202.60
High: 1,215.20
Low: 1,195.80
Yest. Close: 1,190.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

British cost agency to take broader view of drug value

* NICE to look at "wider societal impact" of new drugs * Move may mean more positive recommendations in future * But NICE CEO says firms must offer "very best price" By Ben Hirschler LONDON, March 27 (Reuters) - British healthcare cost agency NICE is to take a broader view

27 Mar 14 00:01

Merck, Glaxo end co-pay assistance for Obamacare plans

March 26 (Reuters) - Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program. The two drugmakers said their decision, first reported by Bloomberg New

26 Mar 14 22:26

UPDATE 1-Tampering in some US bottles of weight-loss drug Alli - Glaxo

(Updates with company statement, paragraphs 4-7) March 26 (Reuters) - Some bottles of Alli, GlaxoSmithKline Plc's weight-loss drug sold over the counter in the United States, have been tampered with, and the Food and Drug Administration was investigating, the company said on Wednesday. <

26 Mar 14 21:09

UPDATE 1-Danish drug maker Santaris considers U.S. listing -investor

* Sunstone Capital considers listing Santaris Pharma * Decision on IPO will probably be made this year * Sunstone says prefers U.S. listing due to better analyst coverage (Adds financial details) By Teis Jensen and Ole Mikkelsen COPENHAGEN, March 26 (Reuters) - Danish ve

26 Mar 14 15:42

GSK receives European green light for diabetes treatment

European regulatory approval has been granted to GlaxoSmithKline's albiglutide treatment for type two diabetes. GSK expects to launch albiglutide, which is branded Eperzan and is still underdoing its US approval process, in several countries in Europe in the second half of the year, with additiona

26 Mar 14 15:34

UPDATE 1-Women struggling to crack glass ceiling in top UK companies-report

* Women now hold fifth of FTSE 100 board positions * Few women on executive committees with only 4 CEOs * Campaigners push for voluntary change, not quotas (Adds new quotes, numbers, after report launch) By Belinda Goldsmith LONDON, March 26 (Reuters) - More women are si

26 Mar 14 15:17

GSK reports tampering of some bottles of weight-loss drug

March 26 (Reuters) - GlaxoSmithKline Plc said some bottles of its weight-loss drug Alli bought in the United States had been tampered with and that the U.S. Food and Drug Administration was investigating. Consumers reported that some bottles bought in stores in seven states contained produc

26 Mar 14 14:17

EU approves GSK's once-weekly diabetes drug

March 26 (Reuters) - GlaxoSmithKline Plc said on Wednesday that it had received European marketing approval for its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. The drug received a positive recommendation from the European Medicines Agency (EMA) in January. <p

26 Mar 14 14:11

UK MIDDAY BRIEFING: Government Completes 2nd Lloyds Bank Stake Sale

LONDON (Alliance News) - The UK government has raised a further GBP4.20 billion from its second sale of <strong>Lloyds Banking</strong> Group PLC shares, meaning it has now recouped GBP7.41 billion of the roughly GBP21 million that taxpayers injected into the bank during the financial crisis.<

26 Mar 14 13:40

UPDATE: Glaxo Pulls European Application For Combined Treatment

LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had withdrawn its European marketing authorisation application for the combined use of Meikinist and Tafinlar for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. This was as a result of the Commit

26 Mar 14 13:20

TOP NEWS: UK Government Raises GBP4.2 Billion From Lloyds Sale

LONDON (Alliance News) - The following is a summary of top news stories Wednesday.<br /><strong>----------</strong><br /><strong>COMPANIES</strong><br />----------<br />The UK government said it has raised GBP4.2 billion in its sale of a second tranche of <strong>Lloyds Banking</strong> Group

26 Mar 14 11:17

GSK melanoma drug combination faces delay in Europe

LONDON, March 26 (Reuters) - A combination treatment from GlaxoSmithKline for melanoma, the deadliest form of skin cancer, has been delayed in Europe after regulators said they needed more information. Britain's biggest drugmaker said on Wednesday it had withdrawn its application and would

26 Mar 14 10:49

Glaxo Withdraws Marketing Application For Mekinist, Tafinlar Combined Treatment

LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had withdrawn its marketing authorisation application for the combined use of Meikinist and Tafinlar for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in Europe. This was as a result of the Commi

26 Mar 14 10:28

GSK withdraws combined-use cancer drug application from EMA

Complaints about insufficient information has led GlaxoSmithKline to temporarily withdraw a European regulatory application for the combined use of two drugs to treat certain cancers. The FTSE 100 company had applied to the European Medicines Agency (EMA) to gain approval to market its trametinib/

26 Mar 14 10:10

Sanofi faces make-or-break verdict on big dengue vaccine bet

* Final Phase III results due by late September * Sanofi hopes to deliver first doses in late 2015 * Sanofi has spent over 1.3 bln euros on project * Sales could top 1 bln euros but project is risky -analysts By Natalie Huet and Noëlle Mennella NEUVILLE-SUR-SAONE, F

25 Mar 14 12:51

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.